Articles by January, 2025

Delek Group, controlled by businessman Yitzhak Tshuva, has reached a significant agreement to acquire control of Isracard, Israel's leading credit card company, for a reported NIS 3.56 billion. The deal follows a previous agreement between Isracard and Menorah Mivtachim, valued at NIS 3.15 billion, which was ultimately canceled after Menorah chose not to improve its offer

The Chief Military Defense Attorney’s Office has confirmed a significant increase in the number of defense attorneys providing legal advice to soldiers and reservists regarding investigations related to the ongoing war. This surge in consultations is linked to multiple investigation mechanisms that have been put in place since the conflict began, including internal military probes and external audits

General Joseph Awan’s election as Lebanon’s new president marks a significant turning point for the country, ending a political deadlock that had lasted more than two years. His rise to power, supported by the United States, Saudi Arabia, and several Arab countries, is expected to prompt increased pressure on Israel to withdraw its forces from southern Lebanon by the end of January, as stipulated in a ceasefire agreement

A new proposal to change the composition of Israel's Judicial Selection Committee, unveiled Thursday by Ministers Yariv Levin and Gideon Sa'ar, has ignited fierce opposition from legal experts, civil society organizations, and opposition politicians. Critics argue that the proposed changes mark a significant step toward a political takeover of the judiciary and threaten the very foundations of Israeli democracy

Prime Minister Benjamin Netanyahu confirmed on Saturday evening that Mossad Director David Barnea will travel to Qatar at the head of a high-ranking delegation to advance negotiations on a hostage deal and a potential ceasefire in Gaza. The trip is part of ongoing international efforts to secure the release of Israeli hostages held by Hamas, to reach a deal by January 20, the deadline for President-elect Donald Trump’s inauguration

Prime Minister Benjamin Netanyahu issued a statement to the Israeli public on Saturday evening, explaining the recent cabinet approval for the hostage release deal. The statement came following a government meeting that reviewed the details of the deal, which has faced both support and opposition from within the coalition

A stabbing attack took place this evening (Tuesday) in the bustling Nahalat Binyamin area of Tel Aviv, leaving four people injured. According to initial reports, a terrorist pulled out a knife and began attacking passersby in two separate locations within proximity. The victims included a 28-year-old man and a 24-year-old man, both of whom were in moderate condition, and two others, aged 24 and 59, who sustained lighter injuries. Emergency medical teams quickly arrived and transported the injured to nearby hospitals

The recent ceasefire in the Gaza Strip, along with the ongoing release of abducted Israeli citizens, marks a pivotal moment in Israel’s recovery following the October 7 attack. On Tuesday, IDF Chief of Staff Herzi Halevi and Southern Command Colonel Yaron Finkelman announced their resignations, signaling the end of their service in the Israeli Defense Forces (IDF)

After months of delays and obstacles from Justice Minister Yariv Levin, Justice Yitzhak Amit was officially appointed as President of the Supreme Court on Sunday, following the seniority system. Justice Noam Solberg was appointed Deputy President in his place. The appointments come amid Levin’s continued efforts to overhaul Israel's legal system, including a push to change the composition of the Judicial Selection Committee, which would grant political leaders more control over judicial appointments

Teva Pharmaceutical Industries has announced impressive results for its most promising innovative drug, Duvakitug, in treating colitis and Crohn's disease. The company revealed today that the drug achieved significantly better-than-expected outcomes in the second phase of clinical trials, outperforming a placebo in key efficacy measures. As a result, Teva's stock surged more than 15% in pre-market trading on the New York Stock Exchange